Skip to main content

Table 3 Expression of angiogenic factors in gastrointestinal cancer cell lines

From: Biomarkers for antitumor activity of bevacizumab in gastric cancer models

Cell line

Sensitivity to bevacizumab

VEGF

PlGF

IL-8

bFGF

COL-16-JCK

+

4430 ± 991

< 15.6

360 ± 171

268 ± 75.3

SC-08-JCK

+

2330 ± 402

< 15.6

< 31.3

145 ± 25.9

GXF97

+

1950 ± 753

< 15.6

362 ± 134

107 ± 63.6

MKN-45

+

1560 ± 310

< 15.6

65.9 ± 9.38

183 ± 43.0

CXF280

+

1480 ± 290

< 15.6

< 31.3

77.6 ± 16.5

SC-09-JCK

+

1020 ± 163

< 15.6

165 ± 60.3

151 ± 13.3

4-1ST

+

706 ± 106

< 15.6

< 31.3

87.7 ± 5.47

MKN-28

+

577 ± 285

16.4 ± 8.22

< 31.3

200 ± 27.8

SC-10-JCK

-

760 ± 80.2

< 15.6

198 ± 96.5

231 ± 105

NCI-N87

-

171 ± 52.5

< 15.6

34.4 ± 10.8

1090 ± 328

SCH

-

< 31.3

1210 ± 205

< 31.3

38.4 ± 18.6

  1. Mean ± SD (pg/mg protein)
  2. The expression of human VEGF, PlGF, IL-8 and bFGF in tumor tissues were examined by ELISA